Valneva SE (NASDAQ:VALN) Sees Significant Growth in Short Interest

Valneva SE (NASDAQ:VALN - Get Free Report) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 30,600 shares, an increase of 111.0% from the November 15th total of 14,500 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily trading volume, of 23,500 shares, the short-interest ratio is currently 1.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of Valneva from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, October 11th.

Valneva Stock Down 0.8 %

VALN stock traded down $0.03 during trading on Thursday, hitting $3.93. 33,926 shares of the company's stock traded hands, compared to its average volume of 13,771. The business has a fifty day simple moving average of $5.07 and a two-hundred day simple moving average of $6.52. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $319.30 million, a P/E ratio of -30.23 and a beta of 1.99. Valneva has a 1 year low of $3.82 and a 1 year high of $10.93.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC increased its position in shares of Valneva SE (NASDAQ:VALN - Free Report) by 33.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,000 shares of the company's stock after acquiring an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.